The impact of vitrectomy on outcomes achieved with 0.19  mg fluocinolone acetonide implant in patients with diabetic macular edema

CONCLUSIONS: These long-term data suggest that the 0.2 μg/day FAc implant is effective in both vitrectomized and non-vitrectomized patients, with a manageable safety profile, and improved VA and reduced supplemental therapies for patients with a suboptimal response to first-line DME therapies. Clinicians may consider utilizing the FAc implant earlier in the DME disease process.PMID:33947233 | DOI:10.1177/11206721211014728

Source: European Journal of Ophthalmology - May 5, 2021 Category: Opthalmology Authors: Albert J Augustin Silvia Bopp Martin Fechner Frank G Holz Dirk Sandner Andrea-M Winkgen Ramin Khoramnia Thomas Neuhann Markus Warscher Martin S Spitzer Walter Sekundo Berthold Seitz Tobias Duncker Christian Ksinsik Helmut H öh Source Type: research